

Summary of Product Characteristics

1 NAME OF THE VETERINARY MEDICINAL PRODUCT

FORTEKOR 20 mg film-coated tablets for dogs

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance: Benazepril hydrochloride 20 mg

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Film-coated tablets.

Reddish orange, ovaloid, slightly biconvex tablets with score on both sides, marked “CG” on one side and “HP” on the reverse.

4 CLINICAL PARTICULARS

4.1 Target Species

Dogs.

4.2 Indications for use, specifying the target species

Dogs:

Treatment of congestive heart failure.

4.3 Contraindications

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

Do not use in pregnancy or lactation (section 4.7).

4.4 Special warnings for each target species

None.

4.5 Special precautions for use

Special precautions for use in animals

No evidence of renal toxicity of the veterinary medicinal product has been observed in dogs during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician.

Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

4.6 Adverse reactions (frequency and seriousness)

In double-blind clinical trials in dogs with congestive heart failure, FORTEKOR was well tolerated with an incidence of adverse reactions lower than observed in placebo-treated dogs.

A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.

In dogs with chronic kidney disease, FORTEKOR may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

4.7 Use during pregnancy, lactation or lay

Do not use during pregnancy or lactation. The safety of FORTEKOR has not been established in breeding, pregnant or lactating dogs. Embryotoxic effects (foetal urinary tract malformation) were seen in trials with laboratory animals (rats) at maternally non-toxic doses.

4.8 Interaction with other medicinal products and other forms of interaction

In dogs with congestive heart failure, FORTEKOR has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.

In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR and other anti-hypertensive agents (e.g. calcium channel blockers, β -blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc) should be monitored closely and treated as necessary.

Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.

4.9 Amounts to be administered and administration route

FORTEKOR should be given orally once daily, with or without food. The duration of treatment is unlimited.

Dogs:
FORTEKOR should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the following table:

Weight of dog (kg)	FORTEKOR 20 mg	
	Standard dose	Double dose
> 20 - 40	0.5 tablet	1 tablet
> 40 - 80	1 tablet	2 tablets

The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

FORTEKOR reduced erythrocyte counts in normal dogs when dosed at 150 mg/kg once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in dogs.

Transient reversible hypotension may occur in cases of accidental overdose. Therapy should consist of intravenous infusion of warm isotonic saline.

4.11 Withdrawal Period(s)

Not applicable.

5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: ACE Inhibitors, plain. ATCvet code: QC09AA07

5.1 Pharmacodynamic properties

Benazepril hydrochloride is a prodrug hydrolysed *in vivo* to its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

FORTEKOR causes long-lasting inhibition of plasma ACE activity, with more than 95% inhibition at peak effect and significant activity (>80% in dogs) persisting 24 hours after dosing.

FORTEKOR reduces the blood pressure and volume load on the heart in dogs with congestive heart failure.

5.2 Pharmacokinetic properties

After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (T_{\max} 0.5 hour in dogs) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. The systemic bioavailability is incomplete (~13% in dogs) due to incomplete absorption (38% in dogs) and first pass metabolism.

In dogs, peak benazeprilat concentrations (C_{\max} of 37.6 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a T_{\max} of 1.25 hours.

Benazeprilat concentrations decline biphasically: the initial fast phase ($t_{1/2}$ =1.7 hours in dogs) represents elimination of free drug, while the terminal phase ($t_{1/2}$ =19 hours in dogs) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. Benazepril and benazeprilat are extensively bound to plasma proteins (85-90%), and in tissues are found mainly in the liver and kidney.

There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs. Repeated administration of FORTEKOR leads to slight bioaccumulation of benazeprilat (R =1.47 in dogs with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs).

Benazeprilat is excreted 54% via the biliary and 46% via the urinary route in dogs. The clearance of benazeprilat is not affected in dogs with impaired renal function and therefore no adjustment of FORTEKOR dose is required in either species in cases of renal insufficiency.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Silica, colloidal anhydrous
Cellulose, microcrystalline
Hydrogenated castor oil
Lactose monohydrate
Maize starch, pregelatinised
Crospovidone
Hypromellose
Iron oxide yellow (E172)
Iron oxide red (E172)
Polyethylene glycol 8000
Talc
Titanium dioxide (E171)

6.2 Incompatibilities

Not applicable.

6.3 Shelf-life

Shelf-life of the veterinary medicinal product as packaged for sale: 4 years

6.4 Special precautions for storage

Store in a dry place.

Each time an unused half tablet is stored, it should be returned to the open blister space inserted back into the cardboard box and kept in a safe place out of the reach of children.

6.5 Nature and composition of immediate packaging

PVC/PE/PVDC/aluminium blister containing 14 film-coated tablets.
Cardboard box with 1 blister (14 tablets).

6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with national requirements.

7 MARKETING AUTHORISATION HOLDER

Elanco Europe Ltd.
Lilly House
Priestley Road
Basingstoke
Hampshire
RG24 9NL
United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

VPA 10397/010/003

9 DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 7th December 1995
Date of last renewal: 7th December 2005

10 DATE OF REVISION OF THE TEXT

November 2012
April 2016